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Abstract
Background: Heart failure with preserved ejection fraction is closely associated with diastolic dysfunction and
related to obesity and female sex. We investigated whether adiponectin, an adipocyte-secreted protein hormone
with cardioprotective effects, was associated with indices of diastolic dysfunction, and whether the association was sex
dependent.
Methods: We conducted a cross-sectional study on 1165 women and 896 men without diabetes. We stratified
the multivariable adjusted logistic regression analyses and the fractional polynomial regression analyses according to sex,
with echocardiographic markers of diastolic dysfunction as dependent variables, and adiponectin as the independent
variable of interest.
Results: Decreased adiponectin was associated with higher odds of average tissue Doppler e’ < 9 in women (odds ratio
[OR] 1.17 per 1 μg/mL adiponectin decrease, 95% confidence interval [CI] 1.04–1.30), but not in men (p for interaction
with sex 0.04). Women, but not men, had higher odds of E/e’ ratio≥ 8 with lower adiponectin (OR 1.12 per 1 μg/mL
adiponectin decrease, 95% CI 1.02–1.24, p for interaction with sex 0.04). Adiponectin in the lower sex-specific tertile was
associated with increased odds of concentric left ventricular hypertrophy in women (OR 2.44, 95% CI 1.03–5.77), but with
decreased odds in men (OR 0.32, 95% CI 0.11–0.88, p for interaction with sex 0.002), and decreased odds of eccentric
hypertrophy in men only (OR 0.53, 95% CI 0.33–0.88, p for interaction with sex 0.02). Adiponectin in the lower sex-specific
tertile was associated with moderately enlarged left atria in women only (OR 1.43, 95% CI 1.01–2.03, p for interaction with
sex 0.04). Finally, adiponectin had a non-linear relationship with left ventricular mass in women only, with exponentially
increasing left ventricular mass with lower adiponectin levels (p for interaction with sex 0.01).
Conclusions: Low adiponectin was associated with higher odds of indices of diastolic dysfunction in women, but lower
odds of indices of diastolic dysfunction in men. Lower adiponectin was associated with increased left ventricular mass in
women only.
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Background
Diastolic dysfunction (DD) is a condition characterized
by abnormal cardiac relaxation, stiffness or filling. Heart
failure (HF) with preserved ejection fraction (HFpEF) is
a clinical syndrome with symptoms and signs of HF, but
with normal or only mildly reduced ejection fraction,
and is closely associated with DD [1]. In developed
countries, the prevalence of HF is about 1–2% of the
adult population, and ≥ 10% among persons > 70 years of
age [1]. About half of HF patients have HFpEF [2]. The
EURObservational Research Program: the Heart Failure
Pilot Survey (ESC_HF Pilot) conducted a prospective
1-year survey among 136 cardiology centers in 12
countries with over 5.000 HF patients enrolled [3].
The all-cause mortality rate after 1 year was 13.4% in
acute HFpEF and 5.9% in chronic, stable HFpEF. DD
in itself, not accompanied by HF, is associated with
increased all-cause mortality, and it is often asymptomatic
[4]. Despite HFpEF being a major and growing health prob-
lem in the USA and Europe, the understanding of this
condition is still scarce and there is no medical treatment
of proven benefit for HFpEF [5]. In particular, HFpEF is
associated with female sex‚ increasing age and obesity [1].
The reasons for the female preponderance for HFpEF re-
main unsolved [6]. It is therefore of interest to examine fea-
tures associated with DD, among them metabolic risk
factors, for better understanding of possible sex-specific
mechanisms leading to HFpEF.
Adipose tissue is an endocrine organ that produces a
range of biologically active substances, such as the
adipokines. They constitute a group of protein hormones
with functions in the regulation of energy metabolism,
insulin sensitivity, inflammation, atherosclerosis and cell
proliferation [7]. Biologically important members
include, among others, tumor necrosis factor-α,
interleukin-6, interleukin-10, omentin, leptin and adipo-
nectin [8]. The latter is abundantly produced and se-
creted by adipose tissue, and during the previous decade
adiponectin has been shown to have antidiabetic, anti-
inflammatory, anti-atherogenic and cardioprotective ef-
fects [7]. Low levels of adiponectin are in longitudinal
studies associated with the development of insulin resist-
ance [9] and hypertension [10], and adiponectin is nega-
tively associated with body mass index (BMI) and body-
fat [11]. Reduced plasma adiponectin is associated with
the metabolic syndrome [12] and higher risk of myocar-
dial infarction [13], although, paradoxically, in chronic
HF adiponectin levels tend to be high, and increasing
with disease severity [14]. It has been postulated that uric
acid can affect adipocytes by inducing downregulation of
adiponectin [15]. Thus, there may be a biologically rele-
vant interplay between uric acid and adiponectin.
The relationship between adiponectin and DD has not
been thoroughly investigated. Since there is a female
preponderance for HFpEF, it is of relevance to assess
whether these associations may differ by sex. Therefore,
we wanted to do cross-sectional analyses and examine
the associations between adiponectin and echocardio-
graphic indices of DD in a large cohort of men and
women from the general, non-diabetic population.
Methods
Study population
The Tromsø Study is a population-based, prospective
study of various health issues and chronic diseases. It
consists of seven surveys referred to as Tromsø 1-7,
which have been conducted in the municipality of
Tromsø, Norway, from 1974 to 2016 [16]. The population
of the present study is the participants of the sixth wave of
the Tromsø Study, conducted in 2007–2008 [17]. A total of
12,984 subjects (6930 women and 6054 men, 65.7% of the
invited population) took part in the survey. All individuals
who had attended the extended study of the fourth wave of
the Tromsø Study, and were aged 50–62 years or 75–84
years plus a 20% random sample of persons aged 63–74
years (a total of 7206 subjects) were invited to an extended
examination. Of these, 2243 persons were randomly se-
lected for echocardiography. We excluded the subjects with
prevalent diabetes at baseline (n = 182; defined as HbA1c ≥
6.5%, non-fasting glucose ≥ 10.0 mmol/L, under anti-
diabetic treatment or self-reported diabetes). This left 2061
subjects in the final cohort.
Measurements
The subjects completed a questionnaire, which provided
information on physical activity, prevalent diabetes,
smoking habits and use of medication, as previously de-
scribed [16, 17]. Use of blood pressure lowering drugs
was assessed through self-report (questionnaire) based
on the question “Do you use, or have you used blood
pressure lowering drugs? Currently/Previously but not
now/Never used”. Participants also reported drugs used
on a regular basis the preceding four weeks; this was
coded according to the Anatomical Therapeutic
Chemical (ATC) classification system version 2007
(http://www.whocc.no/). We classified smoking habits
as current smokers and non-smokers, and physical
activity as active (≥ 1 h physical activity with prominent
perspiration or breathlessness per week) or inactive (all
others). We calculated BMI as weight (kg)/height (m)2.
Blood pressure was recorded after a two minutes rest in 1-
minute interval triplicate by an automated device (Dinamap
ProCare Monitor 300, GE Healthcare, Norway). We used
the mean of the second and the third measurement. Blood
samples were non-fasting. Total adiponectin was analyzed
by an ELISA method (DY1065 kit from R&D Systems, Inc.,
Minneapolis, MN) in serum that had been stored at -70°.
Uric acid, serum total cholesterol, cystatin C, triglycerides,
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HbA1c and serum creatinine were analyzed as previously
described [17, 18]. Urine was collected and analyzed as
previously described [18], and the median value of three
albumin-creatinine ratio values was used, calculated from
urine albumin and creatinine of first-void morning urine
samples taken on three consecutive days. We calculated the
estimated glomerular filtration rate (eGFR) according to the
CKD-EPI creatinine-cystatin C equation [19].
Echocardiography
Transthoracic Echocardiography was performed with an
Acuson Sequoia C512 Ultrasound System (Siemens
Medical Solutions. Mountain View, California, USA)
with a combined 3.5 MHz second harmonic ultrasound
and 2.5 MHz Doppler probe. M-mode, 2D and Doppler
echocardiographic recordings were obtained and ana-
lyzed for all participants. A sonographer was the primary
performer of the echocardiography examinations, with
an experienced cardiologist as backup and supervisor.
Measurements were done online by the sonographer as
the recording was done. The measurements were also
done online for the intraobserver and interobserver
study where the reproducibility of measurements was
assessed by new recordings as basis for comparison.
Mean intraobserver variability ± standard deviation (SD)
for the sonographer for E/A ratio was 0.007 ± 0.28, for
left atrial (LA) diameter 0.01 ± 0.49 cm, and for E-wave
deceleration time (EDT) 6 ± 53 ms. The mean interob-
server variability ± SD between the sonographer and the
cardiologist was 0.015 ± 0.29 for E/A ratio, 0.04 ± 0.38 cm
for LA diameter, and 5 ± 38 ms for EDT.
Left ventricular (LV) mass was calculated by the cube
formula at end-diastole (LV mass = 0.8 x [1.04 x {inter-
ventricular septum thickness + LV internal diameter + pos-
terior wall thickness}3 – {LV internal diameter}3] + 0.6 g)
[20]. Relative wall thickness (RWT) was calculated as (rela-
tive wall thickness = [2 x posterior wall thickness]/LV
internal diameter at end-diastole) [20]. We indexed LA size
and LV mass by body surface area calculated by the Du
Bois formula (body surface area = [weight {kg} 0.425 × height
{cm} 0.725] × 0.007184).
Diastolic dysfunction
We used measurements of LA size, LV remodeling,
tissue Doppler and Doppler of mitral flow as parameters
of DD, and the cut-offs were set according to previously
published data and international guidelines [1, 20–22].
We defined LA size as normal (< 2.2 cm/m2), moder-
ately enlarged (2.2–2.79 cm/m2) and severely enlarged
(≥ 2.8 cm/m2). Isovolumetric relaxation time (IVRT) was
either reduced (< 60 ms), normal (60–110 ms), or pro-
longed (> 110 ms). LV hypertrophy was defined as LV
mass > 95 g/m2 in women and > 115 g/m2 in men. LV
remodeling was defined as normal, concentric remodeling
(no hypertrophy and RWT> 0.42), concentric hypertrophy
(hypertrophy and RWT> 0.42), and eccentric remodeling
(hypertrophy and RWT ≤ 0.42). The early myocardial peak
velocity of the mitral annulus, tissue Doppler e’ wave (the
average of the septal e’ and lateral e’ measurements), was
defined as decreased (< 9 cm/s) or normal (≥ 9 cm/s). E/e’,
the ratio of peak early LV filling (E-wave) and average tissue
Doppler e’ wave, was stratified into normal (< 8) and in-
creased (≥ 8). E/A ratio, the ratio of the E-wave and peak
late LV filling (A-wave), was divided into low (< 1.0),
normal (1.0–2.0) and high (> 2.0). We defined EDT, the de-
celeration time of early filling velocity, into low (< 140 ms),
normal (140–220 ms) and high (> 220 ms).
Statistics
The population characteristics are given as number and
percentage of total or mean ± SD, except for albumin-
creatinine ratio, which is given as median and interquar-
tile range. Independent sample t-tests and chi square
tests were applied to compare baseline variables between
women and men. For each of the indices of DD, we
tested the associations with the continuous variable of
adiponectin or adiponectin divided into the lowest sex-
specific tertile vs. all others, and the covariates sex, age,
waist circumference, mean systolic blood pressure, mean
diastolic blood pressure, physical activity, smoking, use
of blood pressure lowering drugs, total cholesterol, HDL
cholesterol, triglycerides, eGFR, and albumin-creatinine
ratio. In analyses with dichotomized indices of DD, we
employed multivariable binary logistic regression models,
and in analyses assessing markers of DD classified into
more than two categories (i.e. E/A ratio, EDT, IVRT, LV
remodeling and LA size) we used multivariable multi-
nomial logistic regression models, with the normal cat-
egories as references. The indices of DD were the
dependent variables in these analyses, and adiponectin
was the independent variable of interest. We also did the
analyses with a combined variable for DD: average e’
wave < 9 plus LA size ≥ 2.2 cm/m2, an approximation of
a definition of DD given by guidelines [23]. We tested
for interaction between sex and adiponectin for the asso-
ciation with each echocardiographic marker of DD using
two-way cross products between sex and the continuous
variable of adiponectin or the indicator variable of adi-
ponectin divided into lowest sex-specific tertile vs. all
others. With the same covariates as listed above, we
examined the association of adiponectin with the two
continuous variables of cardiac remodeling, LV mass
and LA size, with linear regression analyses. We tested
for non-linearity by applying fractional polynomial
models, which estimated the best prediction of the
outcome variable from the power transformations -2, -1, -
0.5, 0 (log transformation), 0.5, 1, 2, 3, on the same linear
regression models. We tested for interaction between sex
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and adiponectin for the association with the continuous
variables using two-way cross products between sex and
adiponectin as a continuous variable. A two-sided p-value
of < 0.05 was considered significant. We performed all the
analyses with SPSS software (IBM Corp. Released 2015.
IBM SPSS Statistics for Windows, Version 23.0. Armonk,
NY: IBM Corp), except for the polynomial fractional ana-
lyses, which were done with Stata software (StataCorp.




The indices of DD and cardiac remodeling examined in
the present study are listed in Table 1, along with the
number of men and women with each echocardio-
graphic marker of DD.
The population characteristics, specified for sex, are
given in Table 2. Most biometrics, including age, differed
significantly between the sexes. This included the echo-
cardiography parameters, except for E/A ratio. Of the
non-echocardiographic variables, only systolic blood
pressure, eGFR, albumin-creatinine ratio, daily smokers,
and use of blood pressure lowering drugs did not signifi-
cantly differ between the sexes.
Multivariable regression models
Multivariable logistic regressions with the indices of DD
that were significantly associated with adiponectin (i.e.,
average e’ < 9, LA size ≥ 2.8 cm/m2) as the dependent
variables are shown in Table 3. Decreased adiponectin
was associated with significantly higher odds of having
average e’ < 9. On the other hand, lower adiponectin was
associated with reduced odds of severely enlarged LA
size. There were no significant associations between con-
tinuous adiponectin and the indicator variables for E/A
ratio, E/e’ ratio, EDT, IVRT, or LV remodeling, nor for
moderately enlarged atria (not shown).
Table 4 displays the continuous variables for LV mass
and LA size as dependent, and adiponectin as the inde-
pendent variable of interest in multivariable linear
regression models. Adiponectin was significantly and
positively associated with LA size. Figure 1 shows the
result of multivariable fractional polynomial regression
and the non-linear (fractional power 3, p < 0.001) rela-
tionship between adiponectin and LA size, which had a
better fit than the linear model. Uric acid did not inter-
act significantly with adiponectin for any of the analyses.
Sex differences
Significant interaction between adiponectin (continuous
variable) and sex was found for the association with two
markers of DD, average e’ < 9 and E/e’ ratio ≥ 8. Sex
stratified logistic regression analyses for these markers
are illustrated in Fig. 2. Lower adiponectin was associ-
ated with higher odds of average e’ < 9 in women (odds
ratio [OR] 1.17 per 1 μg/mL adiponectin decrease, 95%
confidence interval [CI] 1.04–1.30, p = 0.01), but not
Table 1 Indices of diastolic dysfunction and LV remodeling
Index Normal values Diastolic dysfunction and
LV remodeling
Women with index at
baseline, n (%)
Men with index at baseline,
n (%)
E/A ratio 1.0–2.0 < 1.0; > 2.0 < 1.0: n = 629 (54.0%);
> 2.0: n = 12 (1.0%)
< 1.0: n = 505 (58.8%);
> 2.0: n = 14 (1.6%)
EDT 140–220 ms < 140 ms; > 220 ms < 140 ms: n = 120 (10.3%);
> 220 ms; n = 163 (14.0%)
< 140 ms: n = 73 (8.1%);
> 220 ms; n = 188 (21.0%)
IVRT 60–110 ms < 60 ms; > 110 ms < 60 ms: n = 25 (2.1%);
> 110 ms: n = 23 (2.0%)
< 60 ms: n = 12 (1.3%);
> 110 ms: n = 29 (3.2%)
Average e’ wave ≥ 9 cm/s < 9 cm/s n = 184 (15.8%) n = 125 (14.0%)
E/e’ ratio < 8 ≥ 8 n = 247 (21.2%) n = 149 (16.6%)
LA size < 2.2 cm/m2 Moderately enlarged:
2.2–2.79 cm/m2; severely
enlarged: ≥ 2.8 cm/m2
Moderately enlarged:
n = 319 (27.4%); severely
enlarged: n = 26 (2.2%)
Moderately enlarged:
n = 176 (19.6%); severely
enlarged: n = 14 (1.6%)
LV remodeling LV mass≤ 95 g/m2 in
women or ≤ 115 g/m2
in men, and RWT≤ 0.42
Concentric remodeling:
LV mass≤ 95 g/m2 in
women or ≤ 115 g/m2
in men, and RWT > 0.42;
concentric hypertrophy:
LV mass > 95 g/m2 in
women or > 115 g/m2
in men, and RWT > 0.42;
eccentric hypertrophy: LV
mass > 95 g/m2 in women
or > 115 g/m2 in men,
and RWT≤ 0.42
Concentric remodeling:
n = 45 (3.9%); concentric
hypertrophy: n = 40 (3.4%);
eccentric hypertrophy:
n = 206 (17.7%)
Concentric remodeling:
n = 39 (4.4%); concentric
hypertrophy:
n = 35 (3.9%); eccentric
hypertrophy: n = 147 (16.4%)
Abbreviations: EDT E-wave deceleration time, IVRT Isovolumetric relaxation time, LA Left atrium, LV Left ventricle, RWT Relative wall thickness
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men (OR 0.99, 95% CI 0.85–1.16, p = 0.93), p for inter-
action between adiponectin and sex was 0.04. Lower
adiponectin was associated with higher odds of E/e’
ratio ≥ 8 in women (OR 1.12 per 1 μg/mL adiponectin
decrease, 95% CI 1.02–1.24, P = 0.02), but not in men
(OR 0.90, 95% CI 0.78–1.03, p = 0.13, p for interaction
between adiponectin and sex 0.04).
Figures 3 and 4 display the indices of DD for which
sex and the categorized adiponectin variable inter-
acted significantly, namely LV remodeling and LA
size. Adiponectin values in the lower tertile was asso-
ciated with increased odds of concentric LV hyper-
trophy (OR 2.44, 95% CI 1.03–5.77, p = 0.04) in
women, but in men reduced odds for the same
outcome (OR 0.32, 95% CI 0.11–0.88, p = 0.03, p for
interaction with sex 0.002), compared to normal LV
architecture, as shown in Fig. 3. Moreover, adiponec-
tin in the lower tertile was associated with lower odds
of eccentric LV hypertrophy in men (OR 0.53, 95% CI
0.33–0.88, p = 0.01), but not women (OR 1.07, 95% CI
0.71–1.62, p = 0.74 p for interaction 0.02).
Figure 4 illustrates the ORs of the association between
adiponectin and LA size divided by sex. Compared to
normal LA size, adiponectin in the lower tertile was
associated with moderately enlarged LA in women (OR
1.43, 95% CI 1.01–2.03, p = 0.04), but not in men (OR
1.01, 95% CI 0.64–1.58, p = 0.98, p for interaction with
sex 0.04). There was no significant association between
severely enlarged LA and adiponectin for either sex.
Multivariable fractional polynomial regression revealed
that lower adiponectin was associated with increased LV
mass in women (fractional power -2, p = 0.001), but not
men (p = 0.66, p for interaction with sex 0.01), as
displayed in Fig. 5a and b, respectively.
For a combination variable of DD consisting of
subjects with both LA size ≥ 2.2 cm/m2 and average
e’ < 9, the indicator variable of low adiponectin
(lower sex-specific tertile vs. all others) interacted
with sex (p = 0.03). However, adiponectin did not sig-
nificantly predict this outcome for neither women
(OR 1.39, 95% CI 0.98–1.97, p = 0.07) nor men (OR
0.95, 95% CI 0.61–1.50, p = 0.83).
Table 2 Baseline characteristics of cohort divided by sex (n = 2061)
Women (n = 1165) Men (n = 896) P between sex
Age, years 64.2 ±11.7 65.6 ±10.4 0.004
Adiponectin, μg/mL 4.64 ±2.07 3.16 ±1.48 <0.001
Uric acid, μmol/L 280.2 ±66.3 349.1 ±71.5 <0.001
Systolic blood pressure, mm Hg 141.7 ±26.2 143.5 ±20.6 0.094
Diastolic blood pressure, mm Hg 76.5 ±10.3 81.7 ±10.3 <0.001
BMI, kg/m2 26.4 ±4.3 27.2 ±3.6 <0.001
Waist circumference, cm 91.0 ±11.3 100.1 ±10.2 <0.001
Total cholesterol, mmol/L 5.89 ±1.07 5.57 ±1.11 <0.001
Serum HDL, mmol/L 1.72 ±0.43 1.42 ±0.40 <0.001
Triglycerides, mmol/L 1.37 ±0.70 1.53 ±0.88 <0.001
eGFR, mL/min/1.73 m2 89.6 ±17.9 86.6 ±14.5 0.187
Albumin-creatinine ratio, mg/mmol 0.36 [0.21–0.73] 0.37 [0.17–0.87] 0.798
Daily smoking, n 210 18.0% 141 15.7% 0.171
Physically active, n 316 27.1% 285 31.8% 0.020
Use of blood pressure lowering drugs, n 383 32.9% 312 34.8% 0.354
Left ventricular mass, g/m2 84.1 ±21.5 101.0 ±26.7 <0.001
Left atrial size, cm/m2 2.09 ±0.30 2.02 ±0.28 <0.001
E-wave deceleration time, ms 182.5 ±43.8 193.7 ±51.2 <0.001
E/A ratio 1.02 ±0.34 0.99 ±0.35 0.080
Left ventricular ejection fraction, % 72.1 ±7.8 68.7 ±8.8 0.033
Left ventricular ejection fraction < 50%, n 7 0.6% 14 1.6% 0.032
Average e', cm/s 11.28 ±2.58 10.97 ±2.24 0.005
E/e' ratio 6.88 ±2.09 6.50 ±1.98 <0.001
T-test or chi square were used to compare values between men and women
The Tromsø Study
Values are given as mean (SD), median (IQR), or number (%)
Abbreviations: BMI Body mass index, eGFR estimated glomerular filtration rate, HDL High-density lipoprotein
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Discussion
To our knowledge, this is the first study to demonstrate
sex differences in the association between adiponectin
and DD in a general, non-diabetic population. In this
study of 1165 women and 896 men, we have shown that
a lower adiponectin was associated with higher odds of
indices of DD in women, including e’ < 9, E/e’ ratio ≥ 8,
concentric LV hypertrophy, and moderately enlarged
LA. In addition, lower adiponectin was associated with
higher LV mass in women. These associations were not
found in men. Rather, low adiponectin was associated
Table 3 Multivariable logistic regression models with some indices of diastolic dysfunction as dependent variables
Average e' < 9 LA size≥ 2.8 cm/m2a
Odds ratio 95% CI P value Odds ratio 95% CI P value
Adiponectin (per 1 μg/mL decrease) 1.12 [1.02–1.22] 0.015 0.78 [0.66–0.93] 0.004
Uric acid (per 59 μmol/L increase) 1.08 [0.94–1.25] 0.282 1.68 [1.21–2.32] 0.002
Sex (male vs. female) 0.59 [0.41–0.86] 0.005 0.54 [0.19–1.49] 0.233
Age (per 5 year increase) 1.76 [1.56–1.99] <0.001 2.52 [1.76–3.57] <0.001
Waist circumference (per 5 cm increase) 1.00 [0.93–1.08] 0.971 0.77 [0.91–0.99] 0.009
Mean systolic blood pressure (per 5 mm Hg
increase)
1.05 [1.01–1.09] 0.025 1.01 [0.91–1.11] 0.888
Mean diastolic blood pressure (per 5 mm Hg
increase)
1.15 [1.05–1.25] 0.002 0.95 [0.77–1.16] 0.584
Albumin-creatinine ratio (per 1 mg/mmol
increase)
1.01 [0.99–1.02] 0.334 1.04 [1.01–1.06] 0.007
Total cholesterol (per 1 mmol/L increase) 0.90 [0.77–1.04] 0.142 1.10 [0.75–1.62] 0.615
HDL cholesterol (per 1 mmol/L increase) 1.17 [0.75–1.82] 0.497 0.30 [0.09–1.04] 0.057
Triglycerides (per 1 mmol/L increase) 1.19 [0.94–1.51] 0.146 0.67 [0.29–1.56] 0.352
eGFR (per 5 mL/min/1.73 m2 increase) 1.02 [0.96–1.08] 0.609 1.17 [1.01–1.36] 0.040
Daily smoking (yes vs. no) 1.47 [0.99–2.19] 0.059 1.72 [0.59–5.01] 0.318
Physically active (yes vs. no) 1.08 [0.76–1.53] 0.672 1.42 [0.51–3.90] 0.500
Use of blood pressure lowering drugs
(yes vs. no)
1.26 [0.92–1.71] 0.148 2.17 [0.95–4.93] 0.065
The Tromsø Study
Covariates: Age, sex, waist circumference, mean systolic blood pressure, mean diastolic blood pressure, use of blood pressure lowering drugs, total cholesterol,
HDL cholesterol, triglycerides, eGFR, albumin-creatinine ratio, physically active, daily smoker and uric acid
Abbreviations: eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LA left atrium
aCompared to reference category, LA size < 2.2 cm/m2
Table 4 Linear regression models with parameters of cardiac
remodeling as dependent variables
Adiponectin (per 1 μg/mL increase)
β 95% CI t P value
Left ventricular
mass (g/m2)
−0.59 −1.29 to 0.11 −1.66 0.098
Left atrial size
(cm/m2)
0.013 0.01 to 0.02 3.29 0.001
The Tromsø Study
Covariates: Age, sex, waist circumference, mean systolic blood pressure,
mean diastolic blood pressure, use of blood pressure lowering drugs, total
cholesterol, high-density lipoprotein cholesterol, triglycerides, estimated
glomerular filtration rate, albumin-creatinine ratio, physically active, daily
smoker and uric acid
Fig. 1 Multivariable fractional polynomial regression with left atrial size
as the dependent variable, and adiponectin as the independent variable
of interest. Shaded regions denote 95% confidence interval. Covariates:
Age, sex, waist circumference, mean systolic blood pressure, mean
diastolic blood pressure, use of blood pressure lowering drugs, total
cholesterol, high-density lipoprotein, triglycerides, estimated glomerular
filtration rate, physically active, daily smoker, albumin-creatinine ratio and
uric acid
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with decreased odds of concentric LV hypertrophy and
eccentric LV hypertrophy in men. Except for a severely
enlarged atrium, we found no marker of DD that was as-
sociated with a high adiponectin in women, and con-
versely, we found no marker of DD at all that was
associated with a low adiponectin in men.
Traditionally, high adiponectin levels have been
regarded as favorable in terms of cardiac health, but re-
search has challenged this view, and the role and action
of adiponectin in heart disease is not clear. In general,
low adiponectin has been associated with the develop-
ment of coronary heart disease in healthy subjects [24],
but high adiponectin was a risk factor for severity of HF
and mortality in patients with chronic HF [25]. A
current theory to this equivocal relationship of adipo-
nectin and heart disease is that high levels are beneficent
in healthy subjects, but that adiponectin levels can be
upgraded as a compensatory mechanism in the face of
chronic HF [14]. This may explain, in our study, why in
women low adiponectin was associated with moderately
enlarged LA, but higher adiponectin was associated with
severely enlarged LA. Adiponectin could also increase
simply due to reduced kidney function, which commonly
coexists with HF [26].
To our knowledge, only a few studies have examined
sex differences in the association between adiponectin
and DD. In one paper, a cohort consisting of 193
Fig. 2 Multivariable binary logistic regression models divided by sex
with average e’ < 9 and E/e’ ratio ≥ 8 as dependent variables.
Odds ratio are per 1 μg/mL adiponectin decrease. Whiskers
represent 95% confidence interval. * = p for interaction with sex < 0.05.
Covariates: Age, waist circumference, mean systolic blood pressure, mean
diastolic blood pressure, use of blood pressure lowering drugs, total
cholesterol, high-density lipoprotein, triglycerides, estimated glomerular
filtration rate, physically active, daily smoker, albumin-creatinine ratio and
uric acid
Fig. 3 Multivariable multinomial logistic regression models divided by sex with left ventricular remodeling as the dependent variable. Each category of left
ventricular remodeling displayed is compared to the normal category. Odds ratios are for the individuals in the sex-specific lower adiponectin tertile
compared to the two upper tertiles. Whiskers represent 95% confidence interval. * = p for interaction with sex < 0.05. Covariates: Age, waist circumference,
mean systolic blood pressure, mean diastolic blood pressure, use of blood pressure lowering drugs, total cholesterol, high-density lipoprotein, triglycerides,
estimated glomerular filtration rate, physically active, daily smoker, albumin-creatinine ratio and uric acid
Fig. 4 Multivariable multinomial logistic regression models divided
by sex with left atrial size as the dependent variable. Each category
of left atrial size displayed is compared to normal category, left atrial
size < 2.2 cm/m2. Odds ratios are for the individuals in the sex-specific
lower adiponectin tertile compared to the two upper tertiles. Whiskers
represent 95% confidence interval. * = p for interaction with sex < 0.05.
Covariates: Age, waist circumference, mean systolic blood pressure,
mean diastolic blood pressure, use of blood pressure lowering
drugs, total cholesterol, high-density lipoprotein, triglycerides,
estimated glomerular filtration rate, physically active, daily smoker,
albumin-creatinine ratio and uric acid
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patients undergoing cardiac catheterization for coronary
artery disease was divided by sex. The authors found a
negative relationship between adiponectin and DD (eval-
uated by correlation with LV end-diastolic pressure, and
Tau, the time constant of the decrease in LV pressure),
but they could not report a significant sex difference in
this association [27]. A recent population based study of
556 individuals did not find any association between DD
and adiponectin for either sex [28]. The study categorized
patients into DD grades: grade I (mild DD) if lateral e’ <
10 cm/s, E/A ratio < 0.8, EDT > 200 ms, and E/e’ ratio ≤ 8;
grade II (moderate DD) if lateral e’ < 10 cm/s, E/A ra-
tio 0.8–1.5, EDT 160–200 ms, and E/e’ ratio 9–12;
and grade III (severe DD), if lateral e’ < 10 cm/s, E/A
ratio ≥ 2, EDT < 160 ms, and E/e’ ratio ≥ 13. The fact that
our population was much larger and used somewhat dif-
ferent DD indices, may account for the divergent results.
Experimental studies may shed some light on the effects
of adiponectin on the development of DD and the sex dif-
ferences in the overall action of adiponectin. In adiponectin
deficient mice, pressure overload resulted in concentric
cardiac hypertrophy and mortality to a greater degree than
in pressure overloaded wild type [29]. Another study in adi-
ponectin deficient mice, in which the animals were
subjected to aldosterone-induced hypertension in addition
to uninephrectomy, showed that hypoadiponectinaemia
exacerbated hypertension-induced DD with increased LV
mass, increased E/A ratio, reduced e’ wave and increased
E/e’ ratio in the adiponectin deficient mice compared to
the wild type [30]. Transgenic mice that overexpressed
adiponectin were protected from DD after pressure over-
load compared to wild type [31]. Induced activity of the en-
zyme heme oxygenase-1 (HO-1) has been associated
with reduced oxidative stress, increased insulin sensi-
tivity and increased adiponectin levels [32, 33]. One
study pharmacologically induced HO-1 in both lean
and obese female and male mice, and discovered that
although female obese mice had higher levels of several
inflammatory cytokines than male obese mice, HO-1 in-
duction and a subsequent increase in adiponectin, reduced
inflammatory cytokines to similar levels in females and
males [34]. Similar results were found in another study on
obese female and male mice that administered a peptide
that increased HO-1 and adiponectin levels [35], and the ef-
fects were independent of body weight in the female
animals only. In both these studies, adiponectin levels were
similar in obese male and female mice, but treatment raised
adiponectin levels significantly higher in females than
males. These animal studies are suggestive of sex differ-
ences in concentration/production and activity of adiponec-
tin, especially in the obese subjects. Indeed, adiponectin
levels are generally higher in women than in men, perhaps
in part because of a negative correlation with testosterone
[36], and post-menopausal women have lower levels of adi-
ponectin [37]. Also in humans, the relative sex difference in
adiponectin is less pronounced in obese than non-obese
[38]. Additionally, one study found DD to be more strongly
correlated with abdominal adiposity in women than in men
[24]. Although several studies have confirmed a positive
correlation between insulin sensitivity and adiponectin in
both sexes [38], one study found a lower number of adipo-
nectin receptors in female skeletal muscle and speculates
that this may result in a reduced insulin sensitizing effect of
adiponectin in women compared with men [39]. Adiponec-
tin can be separated into three complexes: low molecular
weight form, middle molecular weight form, and high mo-
lecular weight form (HMW), and some suggest that the ra-
tio of HWM to total adiponectin levels is more closely
associated with insulin sensitivity than total levels alone
[40]. HMW adiponectin was lower in men, but not in
Fig. 5 Multivariable fractional polynomial regression with left ventricular mass as the dependent variable, and adiponectin as the independent
variable of interest with cohort divided into women (a) and men (b). Shaded regions denote 95% confidence interval. Covariates: Age, waist
circumference, mean systolic blood pressure, mean diastolic blood pressure, use of blood pressure lowering drugs, total cholesterol, high-density
lipoprotein, triglycerides, estimated glomerular filtration rate, physically active, daily smoker, albumin-creatinine ratio and uric acid
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women, with diabetes and coronary artery disease [41]. The
dissimilarity in adiponectin levels between men and women
may be due solely to a higher level of HWM in women
than men [40]. Unfortunately, only total adiponectin was
available in our survey, so it was not possible for us to
examine the HMW fraction in relation to DD and sex. In
sum, it is possible that discrepancies between men and
women in adipose tissue activity, distribution of adiponec-
tin receptors and HMW adiponectin content have contrib-
uted to the sex differences in the association between
adiponectin and DD reported in our study. With the above
in mind, the facts that our cohort had a mean BMI > 25 kg/
m2, i.e. within the overweight range, and a mean age in the
mid-sixties may have influenced our results. The relation-
ship between adiponectin, obesity, sex, and organ damage
is a complex one and further studies are clearly needed.
The main strengths of this study were the large cohort
size, the high attendance rate and the ability to correct for
several covariates, including eGFR and use of antihyperten-
sive medication, and the use of the newest guideline based
definitions of DD. The most important limitation was its
cross-sectional design. Other relevant limitations include
the lack of fasting blood samples, and the single measure-
ment of total adiponectin available. A quantification of
HMW adiponectin could have provided more data in our
models. Moreover, our estimation of LA was based on the
diameter; LA volume measurements may have yielded add-
itional information. Data on tricuspid regurgitation velocity
would also have strengthened the study. Our exclusion of
subjects with diabetes may be a further limitation. The fact
that our cohort largely consisted of middle-aged, healthy
Northern Europeans limits the study’s generalizability to
other ethnic groups.
Conclusions
Low adiponectin was associated with several indices of
DD and increased LV mass in women, but not in men.
Whether these associations are clinically relevant and
could influence prediction and treatment of DD, should
be further explored.
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